Evidence map›Paper›PMID 25322826›Full record

Trial reportRadiation oncology (London, England)2014

Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study.

Hiroshi K Inoue, Hiro Sato, Yoshiyuki Suzuki, Jun-ichi Saitoh, Shin-ei Noda, Ken-ichi Seto, Kota Torikai, Hideyuki Sakurai, Takashi Nakano

Abstract readClinical Trial
In one paragraph

Trial report in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. Two-Day Fraction Gamma Knife Radiosurgery for Large Brain Metastasis.Journal of Korean Neurosurgical Society · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. CyberknifeJournal of cancer research and clinical oncology · 2021
    Article
  8. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.International journal of radiation oncology, biology, physics · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroshi K InoueCyber Center, Kanto Neurosurgical Hospital, 1120 Dai, Kumagaya, Saitama, 360-0804, Japan. chair.ino@instno-med.org.
Hiro SatoCyber Center, Kanto Neurosurgical Hospital, 1120 Dai, Kumagaya, Saitama, 360-0804, Japan. h-sato0808@hotmail.co.jp.
Yoshiyuki SuzukiDepartment of Radiation Oncology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan. ysuzui@fmu.ac.jp.
Jun-ichi SaitohDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. junsaito@gunma-u.ac.jp.
Shin-ei NodaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. snoda@gunma-u.ac.jp.
Ken-ichi SetoCyber Center, Kanto Neurosurgical Hospital, 1120 Dai, Kumagaya, Saitama, 360-0804, Japan. cyber@kantounouge.com.
Kota TorikaiGunma University Heavy-ion Medical Research Center, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. torikai@gunma-u.ac.jp.
Hideyuki SakuraiProton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 365-8576, Japan. hsakurai@pmrc.tsukuba.ac.jp.
Takashi NakanoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. cyber@kantounouge.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications.

methodsEighty-eight patients with large brain metastases ≥10 cm(3) in critical areas treated from January 2010 to February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less than 7 cm(3) for individual lesions. Univariate and multivariate analyses were conducted.

resultsAs a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm(3) (median, 16.2 cm(3)) in volume were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to compare the results according to the tumor volume, the tumors were divided into the following three groups: 1) 10-19.9 cm(3), 2) 20-29.9 cm(3) and 3) ≥30 cm(3). The lesions were treated with a median prescribed isodose of 57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all tumors ≥20 cm(3) were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months). There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis requiring surgical resection.

conclusionOur findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg's necrosis risk line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas.

Indexed as

Dose Fractionation, RadiationAdultAgedAged, 80 and overBrain NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasmsPrognosisProspective StudiesRadiotherapy, ConformalRadiotherapy Dosage

Identifiers

PMID25322826
PMCPMC4203932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.